Experimental studies show these patches may reach more than 80% of the absorption seen with injections, but they are not yet available for clinical use
Community reports cluster around the same picture: most people tolerate moderate doses without issue, and GI complaints track with higher amounts
Small retrospective analysis with reassuring results Very nice reduction in body weight and insulin dose Some improvement in glucose variability, slightly lower averga glucose, no significant effects on time in range, time bellow or above range No safety concerns Larger prospective studies are needed but current data support the use of GLP-1-based therapies in T1DM #type1diabetes #tirzepatide #bodyweight #glucosecontrol #hypoglycemia #timeinrange To view or add a comment, sign in ' Eli Lilly and Company has announced positive topline results from two additional Phase III trials of retatrutide, its investigational first-in-class GIP/GLP-1/glucagon triple receptor agonist for obesity and related metabolic conditions
At the time of this writing, no peer-reviewed human studies demonstrate weight loss or metabolic benefits
TrimRx provides access to GLP-1 receptor agonist medications (semaglutide, tirzepatide) through a fully online process: health questionnaire licensed provider review personalized prescription free home delivery unlimited telehealth check-ins
For this reason, cost is not the only deciding factor, but it remains one of the most important points when comparing both medications